Poster Presentation
Title: AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers
Date and Time:
Monday April 20, 2026 from 9 AM -12 PM PT
Session Category, Title: Clinical Research, Targeted Antigen Therapies and Immunity
Location: Section 49, Board 12, Number 266
Oral Minisymposium Presentation
Title: MUlti-epitope Targeting Tetravalent Antibody (MUTTA™) platform for Developing NextGen ADCs with an Improved Therapeutic Window
Date and Time:
Tuesday April 21, 2026 from 2:30 –4:30 PM PT
Session Category, Title: Clinical Research, Targeted Therapy: Data Driven Approaches and Novel Drugs
Abstract Presentation Number: 6758
Poster Presentation
Title: ExatecanPayload-Based Antibody-Drug Conjugates with a Short Hydrophilic beta-Glucuronidase Cleavable Linker
Date and Time:
Tuesday April 21, 2026 from 2 –5 PM PT
Session Category, Title: Experimental and Molecular Therapeutics, Multi-Axis Antineoplastic Agents
Location: Section 14, Board 15, Number 5757
At Aarvik, we believe improving clinical efficacy and lowering the minimum efficacious dose (MED), while maintaining or improving the maximum tolerated dose (MTD), is a powerful approach to increasing the therapeutic index of ADCs.
Our unique and comprehensive MUTTA™ ADC platform can unlock a large number of tumor antigen targets with low copy numbers, unsuccessfully pursued so far.